{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:20Z","timestamp":1790286920011,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2019.00262","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T04:38:42Z","timestamp":1573533522000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy"],"prefix":"10.3389","volume":"6","author":[{"given":"Sebastian","family":"Krammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanna","family":"Salzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u015fin Sinem","family":"Ba\u011fci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3238\/arztebl.2019.0119","article-title":"Checkpoint inhibitors","volume":"116","author":"Heinzerling","year":"2019","journal-title":"Deutsches Arzteblatt Int."},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-49544-5","volume-title":"Braun-Falco's Dermatology, Venereology and Allergology.","author":"Plewig","year":"2018"},{"key":"B3","first-page":"e349","article-title":"Bullous pemphigoid associated with nivolumab, a programmed cell death 1 protein inhibitor","volume-title":"J Eur Acad Dermatol Venereol.","author":"Kwon","year":"2017"},{"key":"B4","doi-asserted-by":"publisher","first-page":"E296","DOI":"10.3390\/cancers11030296","article-title":"PD-1 inhibitors-related neurological toxicities in patients with non-small-cell lung cancer: a literature review","volume":"11","author":"Mirabile","year":"2019","journal-title":"Cancers."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00384-019-03268-4","article-title":"Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature","volume":"34","author":"Canete","year":"2019","journal-title":"Int J Colorectal Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/2326-6066.Cir-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/cup.12735","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma","volume":"43","author":"Mochel","year":"2016","journal-title":"J Cutan Pathol."},{"key":"B10","first-page":"e90","article-title":"Atypical pemphigus developed in a patient with urothelial carcinoma treated with nivolumab","volume-title":"J Dermatol.","author":"Ito","year":"2019"},{"key":"B11","unstructured":"NastA\n            SporbeckB\n            WormM\n            EmingR\n            GoebelerM\n            HassanzadehR\n          AWMF S2k-Guideline: Diagnosis and Treatment of Pemphigus Vulgaris\/Foliaceus and Bullous Pemphigoid: AWMF-Registry-Number (013-071)2018"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e201800425","DOI":"10.1002\/jbio.201800425","article-title":"Ex vivo confocal laser scanning microscopy: an innovative method for direct immunofluorescence of cutaneous vasculitis","volume":"12","author":"Bagci","year":"2019","journal-title":"J Biophotonics."},{"key":"B13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jbio.201700211","article-title":"Immunofluorescence and confocal microscopy for ex-vivo diagnosis of melanocytic and non-melanocytic skin tumors: a pilot study","volume":"11","author":"Hartmann","year":"2018","journal-title":"J Biophotonics."},{"key":"B14","doi-asserted-by":"publisher","first-page":"15767","DOI":"10.1111\/jdv.15767","article-title":"Ex vivo confocal laser scanning microscopy for bullous pemphigoid diagnostics: new era in direct immunofluorescence?","volume":"2019","author":"Bagci","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1016\/j.jid.2019.07.052","article-title":"049 Simultaneous assessment of histopathology and direct immunofluorescence in pemphigus vulgaris using ex vivo confocal laser scanning microscopy","volume":"139","author":"Bagci","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40259-019-00339-4","article-title":"First-line treatment of non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors","volume":"33","author":"Bylicki","year":"2019","journal-title":"BioDrugs."},{"key":"B17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrurol.2017.190","article-title":"Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition","volume":"15","author":"Siefker-Radtke","year":"2018","journal-title":"Nat Rev Urol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/jco.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00262-019-02321-z","article-title":"Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer","volume":"68","author":"Kehl","year":"2019","journal-title":"Cancer Immunol Immunother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1111\/ijd.13713","article-title":"Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus","volume":"56","author":"Maeda","year":"2017","journal-title":"Int J Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/s0190-9622(08)80079-5","article-title":"Pemphigus foliaceus associated with enalapril","volume":"24","author":"Shelton","year":"1991","journal-title":"J Am Acad Dermatol."},{"key":"B23","first-page":"1166","article-title":"Angiotensin-converting enzyme inhibitor-induced pemphigus: three case reports and literature review","volume-title":"Mayo Clin Proc.","author":"Kuechle","year":"1994"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.5114\/aoms.2015.54857","article-title":"A retrospective study of antihypertensives in pemphigus: a still unchartered odyssey particularly between thiols, amides and phenols","volume":"11","author":"Pietkiewicz","year":"2015","journal-title":"Arch Med Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/cup.13013","article-title":"PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-Report of 4 cases","volume":"44","author":"Chou","year":"2017","journal-title":"J Cutan Pathol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2133.2004.06147.x","article-title":"In vivo blockade of pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades","volume":"151","author":"Sanchez-Carpintero","year":"2004","journal-title":"Br J Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.0303-6987.2006.00523.x","article-title":"How does acantholysis occur in pemphigus vulgaris: a critical review","volume":"33","author":"Lanza","year":"2006","journal-title":"J Cutaneous Pathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.intimp.2017.10.027","article-title":"Current and future treatment options for pemphigus: is it time to move towards more effective treatments?","volume":"53","author":"Tavakolpour","year":"2017","journal-title":"Int Immunopharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"12601","DOI":"10.1111\/aji.12601","article-title":"Management of pemphigus disease in pregnancy","volume":"77","author":"Tavakolpour","year":"2017","journal-title":"Am J Reprod Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/bjd.12474","article-title":"Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients","volume":"169","author":"Tran","year":"2013","journal-title":"Br J Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1634\/theoncologist.2018-0128","article-title":"A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1\/programmed death ligand-1 inhibitors and recommendations for diagnosis and management","volume":"23","author":"Lopez","year":"2018","journal-title":"Oncologist."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00262\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T04:38:45Z","timestamp":1573533525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2019.00262\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":31,"alternative-id":["10.3389\/fmed.2019.00262"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2019.00262","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,12]]},"article-number":"262"}}